Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $389000.0.

  • BioXcel Therapeutics' Non-Current Assets fell 6463.64% to $389000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 4984.02%. This contributed to the annual value of $944000.0 for FY2024, which is 3944.84% down from last year.
  • BioXcel Therapeutics' Non-Current Assets amounted to $389000.0 in Q3 2025, which was down 6463.64% from $546000.0 recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Non-Current Assets registered a high of $3.5 million during Q1 2022, and its lowest value of $389000.0 during Q3 2025.
  • Moreover, its 4-year median value for Non-Current Assets was $1.6 million (2023), whereas its average is $1.8 million.
  • In the last 5 years, BioXcel Therapeutics' Non-Current Assets crashed by 1860.47% in 2023 and then tumbled by 6463.64% in 2025.
  • BioXcel Therapeutics' Non-Current Assets (Quarter) stood at $3.0 million in 2022, then crashed by 47.77% to $1.6 million in 2023, then plummeted by 39.45% to $944000.0 in 2024, then tumbled by 58.79% to $389000.0 in 2025.
  • Its Non-Current Assets was $389000.0 in Q3 2025, compared to $546000.0 in Q2 2025 and $789000.0 in Q1 2025.